Management

Image of Robert J. Hugin

Mr. Hugin serves as Celgene’s Executive Chairman. He assumed that role on March 1, 2016. Before serving as Executive Chairman, Mr. Hugin served as Celgene’s Chief Executive Officer, a position he held since June 2010 and Celgene’s Chairman, a position he has held since June 2011. Mr. Hugin served as President and Chief Operating Officer from May 2006 to June 2010, and was elected by the Board of Directors to serve as a Director in December 2001. Mr. Hugin joined Celgene in June 1999 as Senior Vice President and Chief Financial Officer. Mr. Hugin is a past Chairman of the Board of The Pharmaceutical Research and Manufacturers of America and is a member of the Board of Trustees of Princeton University, Danaher Corporation, The Medicines Company and The Darden Foundation, University of Virginia. He also serves as a member of the Board of Trustees of Atlantic Health System and of Family Promise, a national non-profit network assisting homeless families. Prior to joining Celgene, Mr. Hugin was a Managing Director with J.P. Morgan & Co. Inc. Mr. Hugin received an AB degree from Princeton University in 1976 and an MBA from the University of Virginia in 1985 and served as a United States Marine Corps infantry officer during the intervening period.

Recent Stock Transactions by Robert J. Hugin
Date Type Shares Traded Price Range
Apr 10, 2017 Option Execute 60,000 29.02
Jan 5, 2017 Option Execute 22,708 27.43
Nov 9, 2016 Automatic Sell 100,000 120.00
Jul 28, 2016 Automatic Sell 100,000 110.00
Jun 20, 2016 Automatic Sell 75,000 100.16
May 17, 2016 Disposition (Non Open Market) 27,000 100.34
Apr 29, 2016 Disposition (Non Open Market) 31,110 103.41
Apr 29, 2016 Option Execute 60,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 1,173 n/a
Feb 12, 2016 Disposition (Non Open Market) 1,173 102.45
Jan 15, 2016 Option Execute 22,680 24.81 - 28.50
Apr 30, 2015 Disposition (Non Open Market) 33,184 108.06
Apr 30, 2015 Option Execute 64,000 n/a
Mar 3, 2015 Acquisition (Non Open Market) 57,723 n/a
Mar 3, 2015 Disposition (Non Open Market) 29,928 118.47 - 118.75
Nov 3, 2014 Disposition (Non Open Market) 433,858 107.41
Nov 3, 2014 Automatic Sell 158,000 106.68
Nov 3, 2014 Option Execute 744,400 7.13 - 17.84
May 2, 2014 Disposition (Non Open Market) 15,555 147.40
May 2, 2014 Option Execute 30,000 n/a
Mar 13, 2014 Disposition (Non Open Market) 39,578 156.00
Mar 13, 2014 Option Execute 95,204 12.59 - 59.01
Feb 12, 2014 Acquisition (Non Open Market) 26,747 n/a
Feb 12, 2014 Disposition (Non Open Market) 13,868 160.54
Jun 16, 2013 Disposition (Non Open Market) 3,370 119.36
Jun 16, 2013 Option Execute 6,500 n/a
May 30, 2013 Automatic Sell 68,087 123.58
May 29, 2013 Disposition (Non Open Market) 242,419 123.09
May 29, 2013 Option Execute 378,592 25.68 - 59.01
Apr 13, 2013 Disposition (Non Open Market) 8,658 123.00
Apr 13, 2013 Option Execute 16,700 n/a
Dec 18, 2012 Disposition (Non Open Market) 12,821 80.03
Dec 18, 2012 Option Execute 20,172 25.68
Apr 14, 2012 Disposition (Non Open Market) 7,725 78.32
Apr 14, 2012 Option Execute 16,667 n/a
Nov 23, 2011 Disposition (Non Open Market) 81,012 60.43
Nov 23, 2011 Option Execute 116,444 25.68 - 59.01
Aug 8, 2011 Buy 10,000 52.70
Jan 17, 2011 Option Execute 36,538 25.68
Image of Mark J. Alles

Mr. Alles serves as Celgene’s Chief Executive Officer. He assumed the role on March 1, 2016. Previously he served as President and Chief Operating Officer. Mr. Alles served as Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, following his promotion to Executive Vice President and Chief Commercial Officer in February 2012. Mr. Alles joined Celgene in April 2004 and served as Vice President, Global Hematology Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his 30-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles is a member of the Celgene Board of Directors, the Trustees for the Healthcare Institute of New Jersey (HINJ), the Board of the Biotechnology Innovation Organization (BIO), and the Board of Gilda’s Club NYC, a not-for-profit organization helping the families of people living with cancer.

Recent Stock Transactions by Mark J. Alles
Date Type Shares Traded Price Range
Feb 14, 2017 Acquisition (Non Open Market) 14,447 n/a
Feb 14, 2017 Disposition (Non Open Market) 6,643 117.02
Dec 2, 2016 Disposition (Non Open Market) 3,018 117.63
Dec 2, 2016 Option Execute 6,560 n/a
Apr 29, 2016 Disposition (Non Open Market) 5,062 103.41
Apr 29, 2016 Option Execute 11,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 25,840 n/a
Feb 12, 2016 Disposition (Non Open Market) 11,889 102.45
Jan 29, 2016 Option Execute 21,938 19.24 - 36.96
Dec 17, 2015 Disposition (Non Open Market) 5,370 112.17
Dec 17, 2015 Option Execute 11,670 n/a
Apr 30, 2015 Disposition (Non Open Market) 5,154 108.06
Apr 30, 2015 Option Execute 11,200 n/a
Mar 1, 2015 Disposition (Non Open Market) 4,078 121.53
Mar 1, 2015 Option Execute 8,334 n/a
Feb 12, 2015 Option Execute 27,505 25.77 - 81.56
Feb 6, 2015 Automatic Sell 117,099 120.68
Feb 6, 2015 Acquisition (Non Open Market) 30,404 n/a
Feb 6, 2015 Disposition (Non Open Market) 13,666 118.75
Feb 6, 2015 Option Execute 107,859 25.77 - 81.56
Feb 12, 2014 Acquisition (Non Open Market) 15,188 n/a
Feb 12, 2014 Disposition (Non Open Market) 6,837 160.54
Dec 27, 2013 Disposition (Non Open Market) 3,501 168.93
Dec 27, 2013 Option Execute 7,777 n/a
Nov 1, 2013 Disposition (Non Open Market) 4,502 151.31
Nov 1, 2013 Option Execute 10,000 n/a
Aug 2, 2013 Sell 5,000 146.47
Aug 2, 2013 Option Execute 15,000 62.35 - 70.63
Jul 31, 2013 Sell 96,406 147.01
Jul 31, 2013 Option Execute 96,406 38.47 - 73.92
Apr 13, 2013 Disposition (Non Open Market) 1,791 123.00
Apr 13, 2013 Option Execute 4,583 n/a
Apr 14, 2012 Disposition (Non Open Market) 902 78.32
Apr 14, 2012 Option Execute 3,056 n/a
Feb 15, 2012 Statement of Ownership 0 n/a
Image of Scott A. Smith

Mr. Smith was promoted to President and Chief Operating Officer on April 1, 2017.  Previously, he was President, Global Inflammation & Immunology (I&I).  Mr. Smith joined Celgene in 2008 as Vice President, Global Marketing I&I and was subsequently named Senior Vice President, Global Head of I & I.  From 2003 to 2008 Mr. Smith was with Biovail, holding positions of General Manager Biovail U.S., General Manager Biovail Canada and Global Commercial Head.  As Global Commercial Head, he was responsible for revenue generation, commercial strategies, business development strategy, and input into regulatory and clinical development strategies.  Prior to Biovail, Mr. Smith was with Pharmacia (formerly Upjohn) for 16 years where he held various positions including Vice President U.S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto, and Commercial and Regulatory Head for South East Asia based in Hong Kong.  In January 2017, Mr. Smith was named a Director of Titan Pharmaceuticals, a specialty pharmaceuticals company that develops therapeutics for select chronic diseases utilizing its innovative, long-term, continuous drug delivery platform, ProNeura.  Mr. Smith holds a BSc in Chemistry and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and a Masters of International Business Management from the American Graduate School of International Management (Thunderbird).

Recent Stock Transactions by Scott A. Smith
Date Type Shares Traded Price Range
Dec 23, 2016 Disposition (Non Open Market) 3,318 118.93
Dec 23, 2016 Option Execute 6,400 n/a
Dec 2, 2016 Disposition (Non Open Market) 1,944 117.63
Dec 2, 2016 Option Execute 3,750 n/a
Apr 29, 2016 Disposition (Non Open Market) 4,987 103.41
Apr 29, 2016 Option Execute 10,000 n/a
Dec 17, 2015 Disposition (Non Open Market) 2,592 112.17
Dec 17, 2015 Option Execute 5,000 n/a
Dec 3, 2015 Disposition (Non Open Market) 5,185 106.55
Dec 3, 2015 Option Execute 10,000 n/a
Apr 30, 2015 Disposition (Non Open Market) 3,077 108.06
Apr 30, 2015 Option Execute 6,666 n/a
Nov 30, 2014 Disposition (Non Open Market) 3,458 113.69
Nov 30, 2014 Option Execute 6,670 n/a
Aug 1, 2014 Statement of Ownership 0 n/a
Image of Peter N. Kellogg

Mr. Kellogg is the Executive Vice President and Chief Financial Officer of Celgene, overseeing Financial Planning, Accounting, Tax/Treasury and Investor Relations.  Before joining Celgene, he was Chief Financial Officer and Executive Vice President of Merck & Co. Inc. from 2007 to 2014.  From 2000 to 2007, Mr. Kellogg served as Chief Financial Officer and Executive Vice President of Finance at Biogen, Inc.. Earlier in his career, Peter was a member of the PepsiCo Management for 13 years.  He was the Senior Vice President, PepsiCo E-Commerce at PepsiCo Inc. in 2000 and Senior Vice President and Chief Financial Officer, Frito-Lay International, from 1998 to 2000.  Before that, Peter held various GM and CFO roles in Frito-Lay and Pepsi Cola in the US, Europe, Asia, and Latin America.  Prior to joining PepsiCo, Mr. Kellogg was a senior consultant with Booz Allen & Hamilton and Arthur Andersen & Co.  Since 2007, Mr. Kellogg has served on the Board of Directors of Yield10 (formerly Metabolix, Inc), a public bioscience company focused on developing step change improvements to crop yields to enhance global food security.  Peter received his BSE from Princeton University in 1978 and MBA from The Wharton School in 1982.

Recent Stock Transactions by Peter N. Kellogg
Date Type Shares Traded Price Range
Feb 14, 2017 Acquisition (Non Open Market) 14,684 n/a
Feb 14, 2017 Disposition (Non Open Market) 7,617 117.02
Feb 12, 2016 Acquisition (Non Open Market) 7,822 n/a
Feb 12, 2016 Disposition (Non Open Market) 4,056 102.45
Image of Michael Pehl

Mr. Pehl serves as President, Global Hematology and Oncology. He was promoted to President in March 2016 after serving as Senior Vice President of Global Marketing since July 2014. Mr. Pehl joined Celgene in 2006 as General Manager of Celgene Germany. He subsequently served as Regional Vice President of Central Europe, Vice President, Head of Marketing Europe and Corporate Vice President, Head of Global Marketing. Before coming to Celgene, he spent 14 years at Amgen, Inc., holding various positions in oncology, rheumatology and nephrology in Germany and for Amgen Europe. Mr. Pehl received his Diploma in Molecular Biology and Biochemistry from Ludwig Maximilian University of Munich.

Recent Stock Transactions by Michael Pehl
Date Type Shares Traded Price Range
Dec 2, 2016 Disposition (Non Open Market) 892 117.63
Dec 2, 2016 Option Execute 1,880 n/a
Nov 10, 2016 Sell 22,052 121.03 - 121.15
Nov 10, 2016 Option Execute 20,424 34.70 - 118.57
Jun 15, 2016 Statement of Ownership 0 n/a
Image of Terrie Curran

Ms.  Curran was promoted to President, Global Inflammation and Immunology Franchise, effective April 1, 2017. Previously, she was Head of Worldwide Markets for the I&I Franchise.  Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA. Ms. Curran has over 22 years of industry experience. Before Celgene, she was at Merck where she served as Senior Vice President and General Manager – Global Women's Health business.  At Merck she was responsible for all commercial activities within the global business and led a number of successful global product launches.  Prior to Merck, Ms. Curran was a General Manager at Schering-Plough where she successfully launched Remicade in Switzerland and Australia. She is a Director of Myovant Sciences Ltd, a research stage company focused on women’s health and endocrine disease and a Director of H. Lundbeck A/S, a global pharmaceutical company focused on psychiatric and neurological disorders.  Ms. Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (BAS) from the University of Technology, Sydney.

Image of Rupert Vessey, MA, BM BCh, FRCP, DPhil

Dr. Vessey serves as President of Research and Early Development.  He joined Celgene in January 2015 as Senior Vice President, Translational Development.  Before joining Celgene, Dr. Vessey was Senior Vice President of Early Development and Discovery Sciences at Merck. During his ten years with Merck, Dr. Vessey was responsible for numerous drug development programs and served as Senior Vice President, Early Development and Discovery Sciences, Senior Vice President, Respiratory and Immunology Franchise and Vice President, Drug Discovery and Informatics.  Prior to Merck, he spent five years at GlaxoSmithKline in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.  Dr. Vessey graduated from Oxford University with degrees in Physiological Sciences (MA), Clinical Medicine (BM, BCH) and a DPhil (PhD) in Molecular Immunology.  He is an elected Fellow of the Royal College of Physicians.

Recent Stock Transactions by Rupert Vessey, MA, BM BCh, FRCP, DPhil
Date Type Shares Traded Price Range
Mar 1, 2017 Sell 4,000 124.42
Feb 2, 2017 Disposition (Non Open Market) 1,995 115.54
Feb 2, 2017 Option Execute 5,623 n/a
Nov 22, 2016 Sell 2,500 123.18
Jun 15, 2016 Statement of Ownership 0 n/a
Jun 15, 2016 Statement of Ownership 0 n/a
Image of Gerald F. Masoudi

Mr. Masoudi joined Celgene in May 2015 and was named Executive Vice President, General Counsel and Corporate Secretary on June 1, 2015. He joined Celgene from Covington & Burling LLP, a leading international law firm, where he was a partner and served as co-chair of the Food and Drug practice group. At Covington, he advised multinational companies and trade associations on significant litigation, enforcement, regulatory and public policy matters. Before joining Covington, Mr. Masoudi served as Principal Deputy/Acting Chief Counsel (2004-05) and as Chief Counsel (2007-09) of the U.S. Food and Drug Administration (FDA), where he advised the FDA Commissioner and HHS leadership on regulatory, litigation and enforcement matters under the Food, Drug and Cosmetic Act and related statutes. Before joining the FDA as Chief Counsel, Mr. Masoudi served as Deputy Assistant Attorney General for international, policy and appellate matters in the Antitrust Division of the U.S. Department of Justice (2005-07). Before his government service, Mr. Masoudi was a trial and litigation partner with the law firm Kirkland & Ellis LLP. Mr. Masoudi received his J.D. from The University of Chicago Law School, graduating in 1993 with high honors. He received his B.A. in economics in 1990 from Amherst College.

Image of Jacqualyn A. Fouse Ph.D.

Dr. Fouse serves as a Strategic Advisor to the Celgene Executive Committee.  Dr. Fouse was previously President and Chief Operating Officer from March 2016 to April 2017.  In February 2016, Dr. Fouse was elected to the Board of Directors. Previously she was President, Global Hematology and Oncology since July 2014. Dr. Fouse joined the Company in September 2010 as Senior Vice President and Chief Financial Officer and became Executive Vice President and Chief Financial Officer in February 2012. Before Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, a global agribusiness and food company (Bunge), starting in July 2007. Before Bunge, Dr. Fouse was at Alcon Laboratories serving as Senior Vice President, Chief Financial Officer, and Head of Corporate Strategy at Alcon Laboratories between 2002 and 2007. Dr. Fouse was the Chief Financial Officer at Swissair Group from 2001 to 2002. Dr. Fouse held a variety of senior finance positions at Nestlé S.A. from 1993 to 2001, including serving as Group Treasurer of Nestlé from 1999 to 2001. Dr. Fouse also worked in finance at Alcon from 1986 to 1993 and held several positions, including Manager Corporate Investments and Domestic Finance. Earlier in her career, she worked at Celanese Chemical and LTV Aerospace and Defense. Dr. Fouse earned a B.A. and an M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington. Since 2010, Dr. Fouse has served as a member of the Board of Directors of Dick's Sporting Goods (chairperson of the audit committee), an NYSE-listed company. She served on the Board of Directors of the Perrigo Company (member of the audit committee), an NYSE-listed company, from November 2012 to April 2016.

Recent Stock Transactions by Jacqualyn A. Fouse Ph.D.
Date Type Shares Traded Price Range
Dec 2, 2016 Disposition (Non Open Market) 2,352 117.63
Dec 2, 2016 Option Execute 5,000 n/a
Apr 29, 2016 Disposition (Non Open Market) 5,177 103.41
Apr 29, 2016 Option Execute 11,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 29,219 n/a
Feb 12, 2016 Disposition (Non Open Market) 13,746 102.45
Dec 17, 2015 Disposition (Non Open Market) 3,532 112.17
Dec 17, 2015 Option Execute 7,500 n/a
Apr 30, 2015 Disposition (Non Open Market) 5,292 108.06
Apr 30, 2015 Option Execute 11,200 n/a
Mar 1, 2015 Disposition (Non Open Market) 3,937 121.53
Mar 1, 2015 Option Execute 8,334 n/a
Feb 6, 2015 Acquisition (Non Open Market) 812 n/a
Feb 6, 2015 Disposition (Non Open Market) 812 118.75
May 2, 2014 Disposition (Non Open Market) 3,686 147.40
May 2, 2014 Option Execute 7,800 n/a
Feb 12, 2014 Acquisition (Non Open Market) 416 n/a
Feb 12, 2014 Disposition (Non Open Market) 416 160.54
Oct 1, 2013 Disposition (Non Open Market) 7,796 157.20
Oct 1, 2013 Option Execute 16,500 n/a
May 21, 2012 Buy 1,000 68.92
Nov 1, 2011 Acquisition (Non Open Market) 1,000 63.92
Aug 9, 2011 Buy 1,000 54.13
Aug 5, 2011 Buy 1,000 55.75
Aug 1, 2011 Buy 2,000 59.47
Jun 14, 2011 Buy 2,000 58.26

Stock transaction information provided by EDGAR Online. Celgene Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.